Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer

Inclusion Criteria: * Patients who are 18 years or older; * Patients with histological or, if not possible, cytologic confirmed adenocarcinoma of the pancreas. * Patients with metastatic pancreatic cancer; * Patient with an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) = 2 * Adequate hematopoietic, hepatic and renal function: * Neutrophil count \>= 1.5 x 10\*9/L; * Platelet count \>= 100 x 10\*9/L; * Bilirubin \<= 1.5 x ULN; * AST and/or ALT \<= 2.5 x ULN; * Serum creatinine \<= 1.5 x ULN. * Investigators must ensure that patients enrolled in the study will be available for all study procedures, including tumor biopsy, chemotherapy treatment, and follow up. * Investigators must ensure that patients have the ability to understand the requirements of the study and provide signed informed consent. * Women of childbearing potential and men who wish to participate in the study must agree to use adequate contraception since the signing of informed consent until at least 3 months after stopping the study medication; * Signed Informed Consent. Exclusion Criteria: * Active or uncontrolled infections or serious illnesses or medical conditions that could interfere with patient eligibility for treatment; * History of any psychiatric condition that might impair patient?s ability to understand or to comply with the requirements of the study or to provide informed consent; * Concurrent anticancer therapy; * Pregnant or breast-feeding women (documented methods of birth control are required in those with reproductive potential); * History of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs; * History of life threatening reaction to gemcitabine or abraxane; * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) \<=1. * Previous treatment with chemotherapy or chemoradiotherapy for advanced pancreatic cancer.